Hot Investor Mandate: USA-Based Fund With China-Based Global Innovation Center Invests Broadly in All Life Science Sectors, With Recent Interest in Disease-Modification Therapies

August 18, 2022 ~ Next Phase Admin ~ Leave a comment

A US fund invests in early-stage startups in many industries with a preference for biotech and IT technology. Typical equity investment size ranges from US$0.5-2 million in Seed to Series B stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 5+ deals in the next 12 months and can invest globally with a focus on the US.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in disease-modification therapies, diagnostics and medical devices. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Family Office Manages Evergreen Fund, Investing Up to $10M in Medical Devices Companies in Cardiology, Orthopedics, and More With Strong USA Focus

August 18, 2022 ~ Next Phase Admin ~ Leave a comment

A family office/venture capital firm based in USA manages an evergreen fund that operates free from the constraints of traditional venture capital funds. The firm seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Full Lineup at RESI Boston

August 11, 2022 ~ Next Phase Admin ~ Leave a comment

By Rory McCann, Director of Marketing & Conference Producer, LSN

RESI Boston returns September 21-23, along with the Innovator’s Pitch Challenge (IPC) which is now full! Applications for the IPC are closed early due to the immense volume of interest. The IPC is a pitch competition designed for early-stage companies to pitch directly to a panel of investors who are a fit for their product and stage of development, specifically in the life science and healthcare spaces. The IPC has established itself as a unique opportunity for participating startups to increase their visibility, and is finally returning after more than two years of virtual pitching. Life Science Nation is proud of the number and quality of applicants and look forward to announcing the full list of 50+ finalists ahead of RESI Boston.

While pitch applications are closed, RESI Boston registration is not! Partnering opens later this month, which includes complimentary tutorials on how to use the partnering system, with detailed examples and Q&A. Register for RESI Boston in time to start booking meetings with investors based on fit and sign up to join a tutorial explaining the strengths of the platform and how to make it work for you. Still interested in pitching? Contact us to learn about upcoming pitch events at RESI!

Learn to Leverage IP for Growth at RESI Boston

August 11, 2022August 11, 2022 ~ Next Phase Admin ~ Leave a comment

By Antoinette Lowre, Manager of Business Development, LSN

Husch Blackwell is coming to RESI Boston! Join us September 21 for the Leveraging IP for Growing an Investable MedTech Company panel, hosted by Husch Blackwell, and featuring industry leaders sharing their experiences in order to help other early-stage entrepreneurs. Husch Blackwell is a law firm focused on delivering in-depth solutions to the most complex business challenges. They bring together the best legal minds and reach beyond law to include experienced industry professionals providing a greater perspective to their clients.

The panel is for industry leaders, entrepreneurs, general counsel, and investors. Topics will include how investable healthcare entities leverage intellectual property (IP) to drive growth. Hear from medtech entrepreneurs about their experiences with IP strategy, protection, licensing, and marketing, and how these and other factors have impacted success. Join us for RESI Boston and get to know the team at Husch Blackwell through the panel and their many services for life science entrepreneurs!

Leveraging IP for Growing an Investable MedTech Company
Moderator: Bryan Stewart, Partner, Husch Blackwell

Panelists:

Cambre Kelly PhD, Co-Founder & CEO, Reselute; Co-Founder and Vice President, Research & Technology, restor3d
Adam T.C. Steege, Founder & President, Trio Labs
Timothy J. Skapek, CTO & Co-founder, Protect3d

Hosted by Husch Blackwell, this panel for industry leaders, entrepreneurs, general counsel, and investors explores how investable healthcare entities leverage intellectual property (IP) to drive growth. Hear from medtech entrepreneurs about their experiences with IP strategy, protection, licensing, and marketing, and how these and other factors have impacted success.

Launching and Funding Startups with the Chinese University of Hong Kong

August 11, 2022 ~ Next Phase Admin ~ Leave a comment

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

Life Science Nation (LSN) is collaborating with the Pre-Incubation (PI) Centre at the Chinese University of Hong Kong (CUHK) to deliver an educational workshop on August 23- 24, from 7:00 – 9:00 AM EDT. With a decade of expertise in helping early-stage life science companies fundraise and build strategic relationships, LSN has developed a curriculum delivering several master class workshops to global tech hubs and incubators. Conducted virtually over two days, the workshop will be led by Dennis Ford, CEO of Life Science Nation, and LSN staff members who are experienced in Asia business development. The workshop is catered to new founders and entrepreneurs of early-stage, seed to series B life science companies to navigate their way in launching or progressing their businesses, and covers a wide range of fundamental entrepreneurial concepts:

How to launch a startup entity and perform entrepreneurial due diligence
Branding and messaging
The importance of telling a cogent company story through multiple modalities
Ten myths of fundraising

LSN is honored to work with the CUHK PI Centre and their constituents for the first time. The PI Centre is a university-wide initiative at CUHK that stimulates creativity and entrepreneurship, supporting aspiring entrepreneurs to prepare and fine-tune their startups since 2014. The center will host a gathering to facilitate the delivery of the workshop. We look forward to meeting the entrepreneurs at CUHK and providing a constructive experience to advance the success of their businesses.

20220803_LSN_poster_1920x1080_F

Sign up or find more information about the workshop here. Contact Joey Wong, Research Analyst, Hong Kong Business Development at j.wong@lifesciencenation.com with questions

LSN is open to collaborating with tech hubs and incubators around the globe. Find out more about LSN’s education programs here.

Hot Investor Mandate: USA-Based VC Firm Invests in Life Science Companies From Seed to Series B Rounds, With Strong Interest in AI-Based Technologies

August 11, 2022 ~ Next Phase Admin ~ Leave a comment

A venture capital firm based in the USA invests in companies in Consumer, Crypto and Life Sciences & Digital Health. For companies in the life sciences, the firm generally invests in Seed and Series A/B rounds, committing between $1-10M in capital.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, MedTech, digital health, and R&D services. For therapeutics, the firm will consider therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, MedTech, Digital Health, and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services, and care management platforms.

The firm looks for companies with a strong management team, large market opportunities, and disruptive technology. When investing, the firm is willing to lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm With Offices in North America & Asia Invests in Therapeutics, Diagnostics, and Digital Health in Relation to Cell Therapy and Regenerative Medicine

August 11, 2022 ~ Next Phase Admin ~ Leave a comment

An early stage venture capital firm is dedicated to building next generation companies in the healthcare sector. The fund is focused on the cell therapy and regenerative medicine sector and will consider opportunities encompassing therapeutics, diagnostics, and those harnessing data to revolutionize the sector. The firm partners with passionate teams that are backed by strong scientific platforms and will primarily invest in preclinical stage assets, contributing $1 – 2M initially. With operations in North America and Asia, the fund take a global approach to building value in their portfolio by linking these two important life science markets and leveraging the respective advantages of each ecosystem.

The firm invests exclusively in technologies relating to cell therapy and regenerative medicine, including precision medicine tools and discovery of new treatment modalities. The company can be in therapeutics, diagnostics or digital health. The firm’s primary areas of interest are oncology, autoimmune disorders, CNS, cardiovascular, renal and liver.

Most of the firm’s investments are in companies either located or looking to enter the Japanese market. The firm can lead or co-invest, and will generally take a board seat when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.